Search

A recent study conducted at the College of Medicine focused on the impact of cyclophosphamide therapy on the testis and sexual glands of adult albino rats. The research found that cyclophosphamide treatment led to atrophic and degenerative changes in the male reproductive organs, including a reduction in testosterone levels. Importantly, the study highlighted the potential risk of infertility and gonadal toxicity associated with cyclophosphamide therapy, which may persist even after the treatment is discontinued. For more information, the full article can be accessed through the Al-Mustansiriyah Journal of Pharmaceutical Sciences. [Extracted from the article]

Researchers at Kashan University of Medical Sciences conducted an experimental study on the effects of L-carnitine in reducing reactive oxygen species and apoptotic gene expression in mice treated with cyclophosphamide therapy. The study found that L-carnitine significantly increased Bcl2 gene expression and decreased Bax and Caspase3 gene expression, as well as reduced reactive oxygen species levels in the mice. These findings suggest that L-carnitine may have protective benefits against infertility caused by cyclophosphamide therapy. [Extracted from the article]

The article discusses a clinical trial, NCT06652152, focusing on investigating the mechanism of the R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in treating BCL2/MYC protein double expressor lymphoma. The study aims to explore the pathogenic mechanism of double expressor lymphoma and potential therapeutic targets through biological tests and DNA sequencing. The trial is observational, with a recruitment goal of 400 participants and a completion date of December 30, 2025. The study includes detailed eligibility criteria and contact information for inquiries. [Extracted from the article]

A study conducted at Memorial Sloan-Kettering Cancer Center in New York City examined the impact of fungal infections (FI) on patients undergoing hematopoietic cell transplantation (HCT) with different prophylaxis methods. The research found that FI after HCT is associated with increased morbidity and mortality, with factors such as neutropenia, HLA mismatch, graft-versus-host disease (GVHD), and viral infections increasing the risk of FI. The study concluded that although rates of FI were low with post-transplantation cyclophosphamide (PTCy), FI is linked to a higher risk of death, highlighting the importance of improved management strategies. [Extracted from the article]

Researchers at Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo conducted a study on Graft-Versus-Host Disease (GVHD) prophylaxis in haploidentical hematopoietic cell transplantation (Haplo-HCT) using methotrexate (MTX) with posttransplant cyclophosphamide (PTCY). The study aimed to assess the safety and efficacy of MTX in adult patients with hematologic malignancies undergoing Haplo-HCT. The findings suggest that GVHD prophylaxis with MTX in Haplo-PTCY is safe and well-tolerated, supporting the continuation of the phase II portion of the study. [Extracted from the article]

A recent study conducted at Tanta University in Egypt explored the protective effects of a nanoformulation of chitosan with an ethanolic extract from Spirulina platensis against cyclophosphamide-induced ovarian toxicity in female Wistar rats. The research found that the nanoformulation helped counteract the detrimental effects of oxidative stress and inflammation in ovarian tissue caused by cyclophosphamide treatment. The study concluded that the nanoformulation showed promise in preventing ovarian follicle death and restoring hormonal balance and normal ovarian histological appearance. [Extracted from the article]

Researchers at Siberian Federal University have conducted a study on cyclophosphamide therapy, a widely used antitumor and immunosuppressive drug with potential adverse effects. The study focused on microencapsulating cyclophosphamide into biodegradable polymeric matrices to reduce its toxicity and frequency of administration. The findings showed that the encapsulated cyclophosphamide had reduced cytotoxicity and sustained release properties, offering promising prospects for cancer therapy in the future. The research was funded by the Ministry of Science And Higher Education of The Russian Federation and published in ADMET and DMPK. [Extracted from the article]

A clinical trial, NCT06640582, is investigating the safety and efficacy of combining autologous tumor-infiltrating lymphocytes (TIL) therapy with Pembrolizumab immunotherapy for patients with advanced brain cancer, including gliomas and meningiomas. This personalized treatment approach aims to utilize the patient's own immune cells to combat cancer, similar to the success seen in treating melanoma. The trial's primary endpoint is to determine the objective response rate (ORR), with secondary endpoints including disease control rate (DCR), progression-free survival (PFS), overall survival (OS), duration of response (DOR), and quality of life (QoL). This study offers a novel treatment option for patients with limited therapeutic alternatives. [Extracted from the article]

A patent issued by Johns Hopkins University discusses a method to increase the therapeutic efficiency of oncolytic bacterial therapy for solid tumors. The patent focuses on using immunoregulatory compounds, such as hydroxyurea, to suppress neutrophils before administering anaerobic bacteria to treat tumors. This approach aims to enhance tumor clearance and reduce treatment-related toxicities, addressing the challenges faced in current cancer therapies. The patent provides detailed methods and compounds for treating various types of solid tumors, emphasizing the importance of neutrophil suppression in improving the efficacy of oncolytic bacterial therapy. [Extracted from the article]

Researchers at Taipei Medical University have published a study on mesenchymal stem cells and their potential in treating primary ovarian insufficiency (POI). The study focused on the use of estrogen-priming mesenchymal stem cells to rescue ovarian function and restore circadian rhythm in mice with POI induced by cyclophosphamide. The findings suggest that the secretome of estrogen-responding human placenta-derived mesenchymal stem cells could be a promising therapy for chemotherapy-induced POI and circadian rhythm disruption. The study highlights the importance of considering the estrogen niche in ovarian tissue for effective treatment. [Extracted from the article]

A study conducted at Hiroshima University Hospital explored the impact of immunosuppressive drugs on the efficacy of mesenchymal stem cell therapy for suppressing renal fibrosis. The research found that certain drugs, such as methylprednisolone and cyclophosphamide, interfered with the activation and engraftment of MSCs, reducing their therapeutic effectiveness. The study suggests that patients on these drugs may benefit more from MSCs preactivated with IFN-g or other means. This research provides valuable insights for selecting patients suitable for MSC therapy. [Extracted from the article]

A study conducted at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, examined the impact of mycophenolate mofetil (MMF) dosing on outcomes after haploidentical hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis. The research found that lower MMF dose/kg was associated with reduced rates of relapse and superior progression-free survival (PFS) compared to higher doses. The study suggests that future investigations should explore optimal dosing strategies for MMF in conjunction with the PTCy regimen. [Extracted from the article]

A study conducted at University Hospital Salamanca in Spain focused on chronic graft-versus-host disease (cGVHD) after haploidentical stem cell transplantation with posttransplant cyclophosphamide (PTCy). The research involved a retrospective analysis of 389 patients and found that the incidence and severity of cGVHD were lower compared to HLA-identical transplantation with conventional prophylaxis. Patients who developed moderate cGVHD had higher overall survival and event-free survival rates, suggesting a stronger graft-versus-leukemia effect. Further prospective studies are recommended to confirm these findings. [Extracted from the article]

A clinical trial, NCT06626256, is being conducted to test the safety and efficacy of STIL101 for injection in treating patients with pancreatic cancer, colorectal cancer, renal cell cancer, cervical cancer, and melanoma. STIL101 for injection is an autologous cellular therapy made from the patient's own T cells collected from tumor tissue. The trial aims to determine the safety of administering STIL101 and assess its effectiveness in treating locally advanced, unresectable, or metastatic cancers. The study involves standard therapy, excisional biopsy, and administration of STIL101 along with chemotherapy and interleukin-2. The trial is not yet recruiting participants and is expected to be completed by October 30, 2027. [Extracted from the article]

A recent study conducted by Unigen Inc. explored the potential benefits of a standardized bioflavonoid composition, UP446, derived from Scutellaria baicalensis and Acacia catechu, as a natural supplement for respiratory conditions associated with aging, oxidative stress, and immune stress. The study utilized mouse models to investigate the antioxidative, anti-inflammatory, and immune-regulatory effects of UP446. The results showed that UP446 improved immune response, increased antioxidant capacity, preserved vital immune organs, and reduced NFkB. These findings suggest that UP446 may have potential applications in respiratory conditions involving immune stress. [Extracted from the article]

A recent study conducted by researchers at the Federal University of Mato Grosso in Sinop, Brazil, explored the potential chemoprotective effects of liposomes containing an extract from the leaves of Protium heptaphyllum (P. heptaphyllum) against oxidative damage induced by cyclophosphamide (CPA), a chemotherapy agent with immunosuppressive effects. The study involved male Swiss mice who were pre-treated with P. heptaphyllum liposomes for 14 days before receiving a single dose of CPA. The results showed that the liposomes had an antimutagenic effect on DNA damage caused by CPA and protected against oxidative stress by increasing antioxidant enzymes. The study suggests that P. heptaphyllum liposomes could potentially be used as a cancer chemoprotective agent and may have antioxidant properties. [Extracted from the article]

Researchers from Dalian Medical University in China have conducted a study on the effects of Octopus peptide hydrolysate (OPH) on immune modulation, intestinal integrity, and gut microbial composition in mice with compromised immune systems induced by the anticancer medication cyclophosphamide (CTX). The results showed that OPH improved body weight, organ indices, and histological changes in the colon, thymus, and spleen. OPH also stimulated the secretion of cytokines and antibodies, reduced the ratio of lipopolysaccharide and diamine oxidase in the serum, enhanced goblet cell and mucus production, upregulated the expression of gut tight-junction proteins, and activated the TLR4/NF-kB cascade. Additionally, OPH treatment improved the balance of gut microflora. The findings suggest that OPH could be used as an immunological ingredient in nutritious foods to regulate the immune system and protect against inflammatory diseases. [Extracted from the article]

Researchers at Siirt University conducted a study on the protective effects of selenium (Se) and boron (B) on cyclophosphamide (CP)-induced liver injury in rats. CP is an anticancer drug that can cause damage to normal tissues. The study found that administration of CP led to increased levels of apoptotic markers, oxidative stress indicators, inflammation levels, and liver function markers, while decreasing apoptosis markers, oxidative stress indicator, inflammation, and intracellular antioxidant defense system. However, when Se and B were administered with CP, these changes were reversed, with Se providing slightly better protection against CP damage than B. The study also investigated the protective effects of Se and B on antioxidant markers in silico, with consistent results for some markers but not others. [Extracted from the article]

A study conducted by researchers at the Avera Cancer Institute in Sioux Falls, South Dakota, examined the timing of pegfilgrastim administration in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide (ddAC) chemotherapy. The study found that administering pegfilgrastim on the same day as chemotherapy led to a significant increase in neutropenic complications, including febrile neutropenia, acute care visits, grade >= 3 neutropenia, chemotherapy dose reductions, and antibiotic use. The researchers concluded that pegfilgrastim should be administered the day after chemotherapy in breast cancer patients receiving ddAC. This study provides important insights for healthcare providers and patients regarding the optimal timing of pegfilgrastim administration to prevent chemotherapy-induced febrile neutropenia. [Extracted from the article]

A recent study conducted at the University of Southern California (USC) compared the use of post-transplant cyclophosphamide (PTCy) alone or in combination with mycophenolate mofetil and tacrolimus (PTCy/MMF/TAC) to methotrexate and tacrolimus (MTX/TAC) as graft-versus-host disease (GVHD) prophylaxis in matched-sibling and fully matched-unrelated donor (MSD/MUD) allo-HSCT. The study found that PTCy/MMF/TAC was associated with improved GVHD-free, relapse-free survival (GRFS) and lower incidence of chronic GVHD compared to MTX/TAC. However, overall survival (OS) and disease-free survival (DFS) were comparable across all groups. These findings suggest that PTCy/TAC/MTX may be a more effective GVHD prophylaxis in MSD/MUD allo-HSCT. [Extracted from the article]

This document provides information about a clinical trial for the treatment of multiple myeloma, a type of cancer. The trial aims to test the effectiveness of a combination of drugs and radiation therapy as a lymphodepleting regimen prior to CAR T therapy for multiple myeloma patients with impaired renal function. The trial is set to begin on November 30, 2024, and is expected to be completed by March 31, 2026. The eligibility criteria for participants include having a confirmed diagnosis of multiple myeloma and meeting certain health requirements. The trial is being conducted in the United States and is regulated by the U.S. FDA, with Dr. Michael J Slade from Washington University School of Medicine as the principal investigator. [Extracted from the article]

A recent study conducted by INVIVO Co. Ltd. in South Korea investigated the immune-enhancing effects of fermented soybean food, Cheonggukjang (CGJ), on immunosuppressed rats treated with cyclophosphamide (CP). The study found that oral administration of CGJs for 4 weeks resulted in increased immunity, as evidenced by changes in gut microbiota, blood and serum parameters, cytokine levels, and histology of the spleen. The researchers concluded that both commercial and traditional CGJs can help maintain or promote the body's immunity. This research provides valuable insights into the potential health benefits of CGJ consumption. [Extracted from the article]

This article discusses a clinical trial, NCT06609928, that is testing the safety and effectiveness of FH-FOLR1 CAR T-cell therapy in treating pediatric patients with relapsed or refractory AML. The trial involves modifying a patient's T cells in the lab to attack cancer cells. The study aims to determine if this therapy is safe and tolerable for pediatric patients with recurrent or refractory AML. The trial involves apheresis, chemotherapy, and infusion of FH-FOLR1 CAR T cells, with a 15-year follow-up. Additionally, the document provides alternative names for medical procedures and drugs, which can be helpful for library patrons conducting research on these topics. [Extracted from the article]

A recent study conducted by the Guangdong Academy of Agricultural Sciences in China explored the immunoregulatory mechanisms of tea polysaccharides (TPSs) in mice with cyclophosphamide-induced immunosuppression. The researchers found that TPSs increased body weight, alleviated thymus atrophy, and increased plasma levels of immunoglobulins and cytokines. They also observed that TPSs regulated the gut microbiota structure and diversity and improved metabolic disorders caused by cyclophosphamide. The study suggests that TPSs could be used as novel innate immune modulators in health foods or medicines. [Extracted from the article]

A clinical trial, NCT06613152, is currently underway to assess the safety and effectiveness of HS-IT201 injection in treating advanced solid tumors. The trial involves adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TIL) after lymphodepletion preparative treatment. The study is in its early stages and is not yet recruiting participants. The trial will measure adverse events, objective response rate, time-to-response, duration of response, disease control rate, progression-free survival, overall survival, lymphocyte subpopulation, and TCR repertoire. The study is open to individuals of all genders between the ages of 18 and 75, and contact information for the study is provided. The trial is being conducted by Qingdao Sino-Cell Biomedicine Co., Ltd. [Extracted from the article]

Researchers at Minia University in Egypt have conducted a study on the protective effects of the leukotriene receptor antagonist, montelukast, against placental toxicity induced by the chemotherapeutic agent cyclophosphamide (CYC). Placental insufficiency is a serious complication that affects pregnancy and fetal growth, and CYC can cause multiple injuries, including placental damage. The study involved pregnant rats divided into different experimental groups, and the results showed that montelukast had a protective role in CYC-induced placental injury by modulating the NLRP3/IL-18 signaling pathway and exhibiting antioxidant, anti-inflammatory, and antiapoptotic effects. This research has been peer-reviewed and published in the International Immunopharmacology journal. [Extracted from the article]

A recent study conducted at State University Campinas in Brazil explored the potential benefits of using the beta-adrenergic blocking agent nebivolol to prevent bladder dysfunction induced by cyclophosphamide (CYP) in mice. The researchers found that nebivolol protected against oxidative stress caused by CYP, preventing increases in reactive oxygen species (ROS) generation and lipoperoxidation, as well as reducing superoxide dismutase (SOD) activity. Nebivolol also mitigated the functional alterations induced by CYP, such as increased voiding frequency, decreased voiding interval, and reduced bladder capacity. The study suggests that combining nebivolol with other cytoprotective agents could be a potential strategy to prevent CYP-associated oxidative damage to the bladder during chemotherapy. [Extracted from the article]

A patent application has been published online for a method of treating diffuse large B-cell lymphoma (DLBCL) using a combination therapy. DLBCL is a common type of non-Hodgkin lymphoma, and current treatments have limited effectiveness for high-risk patients. The method involves administering a bispecific antibody along with a standard treatment regimen in 21-day cycles. Different dosing schedules are provided depending on the specific treatment regimen, and the treatment continues until certain response criteria are met or until disease progression or unacceptable toxicity occurs. The method is applicable to different types of DLBCL and patients with specific prognostic scores. [Extracted from the article]

Researchers at Hospital Israelita Albert Einstein have conducted a study comparing immune reconstitution dynamics after hematopoietic stem cell transplantation (HSCT) using two different immunosuppression methods: anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy). The study found that PTCy was associated with later reconstitution of B, T, and NK cells compared to ATG. Additionally, certain cell types were identified as risk factors for acute and chronic graft-versus-host disease (GVHD). This study provides valuable insights into the immune reconstitution process after HSCT and the effects of different immunosuppression methods. [Extracted from the article]

A recent report from the Department of Hematology and Hematopoietic Cell Transplantation in Duarte, California, discusses the use of brentuximab vedotin in the treatment of anaplastic large cell lymphoma and other peripheral T-cell lymphoma subtypes. The study found that incorporating brentuximab vedotin into initial therapy for CD30-positive peripheral T-cell lymphomas improved progression-free survival. The trial involved 48 participants who received cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide followed by brentuximab vedotin consolidation. The treatment was found to be safe and effective in patients with CD30-expressing peripheral T-cell lymphomas. [Extracted from the article]

A study conducted at Hatyai Hospital in Thailand investigated the impact of different dosing strategies of cyclophosphamide on the treatment outcomes of patients with lupus nephritis (LN). Cyclophosphamide is commonly used to treat LN, but lower doses can be prescribed to minimize side effects. The study found that titrating the dose of cyclophosphamide to 0.5 g/m2 resulted in a higher proportion of patients achieving a primary renal response (PRR) at 52 weeks compared to those who received lower doses. Additionally, the titrate group had a lower rate of infection and death associated with LN. The study suggests that titrating the dose of cyclophosphamide can be beneficial for patients with LN initially treated with lower-than-recommended doses. [Extracted from the article]

A recent report from the Nagoya Proton Therapy Center in Japan discusses the impact of cyclophosphamide (CPA) chemotherapy on polyglycolic acid (PGA) spacers used in radiotherapy for pediatric abdominal tumors. The study found that CPA did not cause significant degradation or adverse tissue reactions to the PGA spacer. The research suggests that PGA spacers are beneficial, but further studies are needed to monitor long-term effects in both animals and humans. The study was funded by the Japan Society for the Promotion of Science. [Extracted from the article]

A recent study conducted by researchers at the University of Kashmir in Srinagar, India, has investigated the protective effect of noni fruit juice against memory impairment caused by cyclophosphamide (CYL) therapy in Swiss albino mice. CYL is a commonly used cancer chemotherapeutic agent that can have severe toxic effects. The study found that noni supplementation reduced the risk of memory impairment caused by CYL and reversed the changes in biochemical markers associated with CYL-induced toxicity. The researchers suggest that supplementing with noni alongside CYL may be a helpful treatment strategy for memory impairment caused by CYL. [Extracted from the article]

A recent study conducted at Wroclaw Medical University in Poland examined the interaction between human serum albumin (HSA) and the drugs doxorubicin and cyclophosphamide. The researchers used various techniques including fluorescence and circular dichroism spectroscopy, electrophoretic light scattering, and molecular modeling to analyze the binding of the drugs to HSA. The results indicated the formation of a HSA-Cyp-Dox complex in solution, with hydrophobic or ionic interactions playing a predominant role. The study also found that doxorubicin binds to the same site on albumin with similar free energy of binding, but the stabilization and binding modes of doxorubicin in the Sudlow site I of HSA are different. This research provides valuable insights into the structure and interactions of human serum albumin with these drugs. [Extracted from the article]

A recent study conducted at Texas Tech University Health Sciences Center focused on neuroblastoma, a common solid tumor in children. The researchers used patient-derived xenografts (PDXs) to identify biomarkers that could predict treatment outcomes in high-risk neuroblastoma patients. They analyzed gene expression in PDXs and identified a set of genes associated with drug resistance. The study also found that PDXs established from pre-therapy samples showed a better response to chemotherapy compared to post-mortem progressive disease samples. The findings provide potential targets for reversing drug resistance and offer a valuable tool for preclinical studies in high-risk neuroblastoma patients. [Extracted from the article]

A recent study conducted at Princess Nourah bint Abdulrahman University in Riyadh, Saudi Arabia, investigated the protective potential of shikonin (SHK) on cyclophosphamide (CP)-induced cardiotoxicity in mice. The study found that CP caused various negative effects on the heart, including oxidative stress, inflammation, and apoptosis. However, treatment with SHK reversed these changes and showed a significant protective effect against CP-induced cardiotoxicity. The researchers suggest that shikonin may be used as an adjuvant to cyclophosphamide in cancer treatment, but further research is needed to investigate its effects on cardiotoxicity in distinct animal cancer models. [Extracted from the article]

Researchers from Northside Hospital Cancer Institute in Atlanta, Georgia have conducted a study on the impact of graft-versus-host disease (GVHD) on relapse and non-relapse mortality following post-transplant cyclophosphamide (PTCy)-based transplantation. The study analyzed 335 consecutive haploidentical donor transplantation (HIDT) recipients and found that the development of grade 3 to 4 acute GVHD was associated with lower overall survival and higher non-relapse mortality rates. However, the development of grade 2 acute GVHD had no significant effect on mortality or survival. The researchers concluded that methods of early identification of patients at risk for GVHD are needed to improve prophylaxis. [Extracted from the article]

A clinical trial, NCT06577025, is currently underway to evaluate the effectiveness and safety of different treatment sequences for individuals with standard-risk multiple myeloma. The study aims to assess the rate of response and potential cure at 5 years, as well as progression-free survival. Secondary outcome measures include overall response rate, duration of response, and overall survival. The trial is ongoing and is expected to be completed by July 2030. This study provides valuable information for individuals with multiple myeloma and their healthcare providers in determining the most effective treatment options. [Extracted from the article]

The article presents the discussion on study revealing that the combination of cyclophosphamide and thiotepa in hematopoietic cell transplant conditioning significantly increases the risk of transplant-associated thrombotic microangiopathy, with higher incidences observed in both allogeneic and autologous transplants. Topics include the impact of specific conditioning agents on TA-TMA risk; and comparative incidence rates.

A new study conducted by researchers at Kochi University School of Medicine in Japan examines the effects of cyclophosphamide (CY) administration on ovarian function in pediatric patients with connective tissue diseases. The study involved a systematic scoping review of six observational studies on systemic lupus erythematosus patients. While no clear difference was found between CY and non-CY groups in terms of clinical ovarian dysfunction, there were statistical differences in hormonal profiles. The review suggests that CY use in childhood may not have clinically significant effects on ovarian function, but further investigation is needed on its impact on hormonal levels, fertility, and pregnancy outcomes. [Extracted from the article]

A recent study conducted by researchers at Memorial Sloan-Kettering Cancer Center examined the use of chemotherapy regimens for early-stage breast cancer over a 14-year period. The study analyzed data from over 34,000 women treated between 2006 and 2019 and found that the use of National Comprehensive Cancer Network (NCCN)-guideline regimens increased over time, while the use of non-guideline regimens and time-discordant regimens decreased. The most common regimen in 2006 was AC-T (cyclophosphamide-doxorubicin, paclitaxel), but by 2019, TC (cyclophosphamide-docetaxel) had become the most prevalent. These findings provide valuable insights into the landscape of chemotherapy delivery in community healthcare settings. [Extracted from the article]

A recent study conducted at Sun Yat-sen University in Guangzhou, China, explored the use of a combination treatment for pediatric patients with relapsed/refractory solid tumors. The study utilized a regimen of vincristine, pegylated liposomal doxorubicin (PLD), and cyclophosphamide (VPC), which had not been previously studied in pediatric patients. The primary goals of the study were to determine the safety and maximum tolerated dose of PLD, as well as the recommended phase 2 dose for further investigation. The study found that the recommended dose of PLD combined with cyclophosphamide and vincristine is 30 mg/m2 once every 3 weeks. The treatment showed promising safety and preliminary efficacy in children with relapsed/refractory solid tumors. [Extracted from the article]

This document provides information about a clinical trial for a drug called AZD0486. The trial aims to assess the safety and efficacy of AZD0486 as a monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies. The trial will include three substudies focusing on different populations with specific types of lymphoma. The trial will evaluate the safety, tolerability, and preliminary efficacy of AZD0486 through various outcome measures. The document also provides a list of keywords related to medical research and discoveries, serving as a resource for library patrons conducting research on these topics. The document is provided by AstraZeneca and was verified in August 2024. [Extracted from the article]

A recent study conducted by researchers at Peking University in Beijing, China, explored the potential of Ganoderma lucidum polysaccharide peptide (GLPP) in protecting male reproductive organs from injury caused by chemotherapy. The study used a mouse model and found that GLPP reduced the negative effects of cyclophosphamide (CP) on reproductive organ function, sperm parameters, and testicular tissue. GLPP also decreased oxidative stress and apoptosis, suggesting that it may have a protective role in spermatogenesis. These findings indicate that GLPP could potentially be developed into a drug to mitigate the reproductive side effects of chemotherapy in male patients. [Extracted from the article]